Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension

References

• Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171
   PubMed Web of Science ®Google Scholar
• Balu S, Thomas J. Incremental expenditure of treating hypertension in the United States. Am J Hypertens 2006;19:810-16
   PubMed Web of Science ®Google Scholar
• Jackson JH, Sobolski J, Krienke R, et al. Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure (JNC 7) Guidelines. J Am Board Fam Med 2008; 21:512-21
   PubMed Web of Science ®Google Scholar
• Chobanian AV. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52
   PubMed Web of Science ®Google Scholar
• Düsing R, Weisser B, Mengden T, et al. Changes in antihypertensive therapy – the role of adverse effects and compliance. Blood Press 1998;7:313-15
   PubMedGoogle Scholar
• Krousel-Wood M, Thomas S, Muntner P, et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357-62
   PubMed Web of Science ®Google Scholar
• Perreault S, Dragomir A, White M, et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med 2009;266:207-18
   PubMed Web of Science ®Google Scholar
• Kettani FZ, Dragomir A, Cote R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009;40:213-20
   PubMed Web of Science ®Google Scholar
• Muszbek N, Brixner D, Benedict A, et al. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract 2008;62:338-51
   PubMed Web of Science ®Google Scholar
• Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446-57
   PubMed Web of Science ®Google Scholar
• Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-75
   PubMed Web of Science ®Google Scholar
• Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-81
   PubMed Web of Science ®Google Scholar
• Novartis International AG Press Release, April 21 2008. Available at: http://www.marketwire.com/press-release/Novartis-International-Ag-845918.html [Last accessed 9 February 2009]
   Google Scholar
• Zusman RM. The pharmacokinetics of angiotensin II receptor blockers (ARBs): Are they different?. Am J Hypertens 1998;11:258A
   PubMedGoogle Scholar
• Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12
   PubMed Web of Science ®Google Scholar
• Barreras A, Turner CG. Angiotensin II receptor blockers. Proc (Bayl Univ Med Cent) 2003;16:123-6
   PubMedGoogle Scholar
• Heran BS, Wong MMY, Heran IK, et al. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension (Review). Cochrane Database Syst Rev 2008;157pp
   Google Scholar
• Graham MR, Allcock NM. Irbesartan substitution for valsartan or losartan in treating hypertension. Ann Pharmacother 2002;36:1840-4
   PubMed Web of Science ®Google Scholar
• Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999;12:414-17
   PubMed Web of Science ®Google Scholar
• Nixon RM, Müller E, Lowy A, et al. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract 2009;63:766-75
   PubMed Web of Science ®Google Scholar
• Mancia G, Korlipara K, Van Rossum P, et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7:135-42
   PubMed Web of Science ®Google Scholar
• Monterosso VH, Rodriguez Chavez V, Carbajal ET, et al. Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators. Adv Ther 2000;17:117-31
   Google Scholar
• Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3:283-91,318
   PubMedGoogle Scholar
• Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004;26:A33-37
   PubMed Web of Science ®Google Scholar
• Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 2009;23:479-89
   PubMed Web of Science ®Google Scholar
• Lloyd A, Schmieder C, Marchant N, et al. Financial and health costs of uncontrolled blood pressure in the United Kingdom. Pharmacoeconomics 2003;21:33-41
   PubMed Web of Science ®Google Scholar
• Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005;112:1651-62
   PubMed Web of Science ®Google Scholar
• NDA 20-898/S-026 Atacand (Candesartan cilexetil) Tablets. Astra Zeneca website. Available at: http://www1.astrazeneca-us.com/pi/Atacand.pdf [Last accessed 9 February 2009]
   Google Scholar
• NDA 20-757/S-038 Avapro (irbesartan) Tablets. FDA approved drug products. Washington, DC: FDA/Center for Drug Evaluation and Research. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020757s038lbl.pdf [Last accessed 9 February 2009]
   Google Scholar
• NDA 21-286/S-010 Benicar (Olmesartan medoxomil) Tablets. FDA approved drug products. Washington, DC: FDA/Center for Drug Evaluation and Research. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021286s010lbl.pdf [Last accessed 9 February 2009]
   Google Scholar
• NDA 20-386/S-045 Cozaar (Losartan potassium) Tablets. Merck website. Available at: http://www.merck.com/product/usa/pi_circulars/c/cozaar/cozaar_pi.pdf [Last accessed 9 February 2009]
   Google Scholar
• NDA 20-850/S-013 Micardis (Telmisartan) Tablets. FDA approved drug products. Washington, DC: FDA/Center for Drug Evaluation and Research. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020850s013lbl.pdf [Last accessed 9 February 2009]
   Google Scholar
• Mann JFE, Schmieder RE, Queen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53
   PubMed Web of Science ®Google Scholar
• Usher-Smith J, Ramsbottom T, Pearmain H, et al. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008;62:480-4
   PubMed Web of Science ®Google Scholar
• Besley JD. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen. Curr Med Res Opin 2008;24:1975-89
   Web of Science ®Google Scholar
• Diovan (valsartan) Tablets. Novartis Pharmaceuticals Corporation website. Available at: www.pharma.us.novartis.com/product/pi/pdf/diovan.pdf [Last accessed 9 February 2009]
   Google Scholar
• Leidig M, Bambauer R, Kirchertz EJ, et al. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Clin Nephrol 2008;69:425-32
   PubMed Web of Science ®Google Scholar
• Sinkiewicz W, Glazer RD, Kavoliuniene A, et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy. Curr Med Res Opin 2009;25:315-24
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Murray AV, Hoppe UC, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin 2008;24:1039-47
   PubMed Web of Science ®Google Scholar
• Maciejewski S, Mohiuddin SM, Packard KA, et al. Randomized, double-blind, crossover comparison of amlodipine and valsartan in African-Americans with hypertension using 24-hour ambulatory blood pressure monitoring. Pharmacotherapy 2006;26:889-95
   PubMed Web of Science ®Google Scholar
• Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 2002;62:1983-2005
   PubMed Web of Science ®Google Scholar
• Biswas PN, Wilton LV, Shakir SW, et al. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. J Hum Hypertens 2002;16:795-803
   PubMed Web of Science ®Google Scholar
• Woodward M. Epidemiology: Study Design and Data Analysis, 2nd edn. Boca Raton, FL: Chapman & Hall/CRC, 2005
   Google Scholar
• Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24
   Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
   Web of Science ®Google Scholar
• Rubin DB, Thomas N. Combining propensity score matching with additional adjustments for prognostic covariates. J Am Stat Assoc 2000;95:573-85
   Web of Science ®Google Scholar
• SAS Institute Inc. SAS/STAT 9.2 User’s Guide, The PHREG Procedure. Cary: NC, 2008
   Google Scholar
• Cochran WG. The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics 1968;24:295-313
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Segal MS, Sautin Y, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 2007;86:899-906
   PubMed Web of Science ®Google Scholar
• Jones JK, Gorkin L, Lian JF, et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995;311:293-5
   PubMed Web of Science ®Google Scholar
• Wilson J, Axelsen K, Tang S, et al. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care 2005;11:SP27-34
   PubMed Web of Science ®Google Scholar
• Atar D, Carmena R, Clemmensen P, et al. Clinical review: impact of statin substitution policies on patient outcomes. Ann Med 2009;41:242-56
   PubMed Web of Science ®Google Scholar
• Meissner B, Dickson M, Shinogle J, et al. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. Manag Care Pharm 2006;12:331-40
   PubMed Web of Science ®Google Scholar
• Khandker RK, Kruzikas DT, McLaughlin TP, et al. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder. J Manag Care Pharm 2008;14:426-41
   PubMed Web of Science ®Google Scholar
• Zachry WM, Doan QD, Clewell JD, et al. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009;50:493-500
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• Conen D, Martina B, Perruchoud AP, et al. High prevalence of newly detected hypertension in hospitalized patients: the value of in-hospital 24-h blood pressure measurement. J Hypertens 2006;24:301-6
   PubMed Web of Science ®Google Scholar
• Chiang WK, Jamshahi B. Asymptomatic hypertension in the ED. Am J Emerg Med 1998;16:701-4
   PubMed Web of Science ®Google Scholar
• Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: a systematic review of the literature. J Gen Intern Med 2002;17:937-45
   PubMed Web of Science ®Google Scholar
• Zeller KR, Von Kuhnert L, Matthews C, et al. Rapid reduction of severe asymptomatic hypertension. A prospective, controlled trial. Arch Intern Med 1989;149:2186-9
   PubMed Web of Science ®Google Scholar
• Gilman BH, Kautter J. Impact of multitiered copayments on the use and cost of prescription drugs among Medicare beneficiaries. Health Serv Res 2008;43:478-95
   PubMed Web of Science ®Google Scholar
• Shea DG, Terza JV, Stuart BC, et al. Estimating the effects of prescription drug coverage for Medicare beneficiaries. Health Serv Res 2007;42:933-49
   PubMed Web of Science ®Google Scholar
• Landsman PB, Yu W, Liu XF, et al. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care 2005;11:621-8
   PubMed Web of Science ®Google Scholar
• Anis AH. Substitution laws, insurance coverage, and generic drug use. Med Care 1994;32:240-56
   PubMed Web of Science ®Google Scholar
• Kasje WN, Timmer JW, Boendermaker PM, et al. Dutch GPs’ perceptions: the influence of out-of-pocket costs on prescribing. Soc Sci Med 2002;55:1571-8
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A Randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906
   PubMed Web of Science ®Google Scholar